仑伐替尼和帕博利珠单抗治疗黏液性苗勒管混合瘤的临床获益：一例报告。
Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report.
机构信息
Cedars Cancer Center, Division of Medical Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
出版信息
Curr Oncol. 2021 Jun 10;28(3):2146-2149. doi: 10.3390/curroncol28030199.
Abstract
A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.
摘要
一位 32 岁的女性患有化疗耐药性苗勒管腺肉瘤，在接受仑伐替尼联合帕博利珠单抗治疗后显示出临床获益。在本病例报告中，我们描述了她的疾病过程和对这种治疗的反应。
相似文献
1
Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report.仑伐替尼和帕博利珠单抗治疗黏液性苗勒管混合瘤的临床获益：一例报告。
Curr Oncol. 2021 Jun 10;28(3):2146-2149. doi: 10.3390/curroncol28030199.
2
Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.帕博利珠单抗联合仑伐替尼与帕博利珠单抗和仑伐替尼单药治疗癌症的安全性和有效性：系统评价。
Int Immunopharmacol. 2021 Feb;91:107281. doi: 10.1016/j.intimp.2020.107281. Epub 2020 Dec 16.
3
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者：一项多中心、开放标签、单臂、2 期临床试验的中期分析。
Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25.
4
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.仑伐替尼联合帕博利珠单抗治疗晚期肾细胞癌、子宫内膜癌和其他选定的晚期实体瘤的 Ib/II 期临床试验。
J Clin Oncol. 2020 Apr 10;38(11):1154-1163. doi: 10.1200/JCO.19.01598. Epub 2020 Jan 21.
5
[New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer].[新药获批：帕博利珠单抗联合乐伐替尼用于晚期或复发性子宫内膜癌患者的二线治疗]
Bull Cancer. 2022 Jul-Aug;109(7-8):740-741. doi: 10.1016/j.bulcan.2022.02.020. Epub 2022 Jun 4.
6
Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not.帕博利珠单抗联合乐伐替尼用于所有晚期子宫内膜癌？可能并非如此。
Int J Gynecol Cancer. 2022 Apr 4;32(4):579. doi: 10.1136/ijgc-2022-003419.
7
Lenvatinib and pembrolizumab in advanced gastric cancer.乐伐替尼与帕博利珠单抗治疗晚期胃癌
Lancet Oncol. 2020 Aug;21(8):1004-1005. doi: 10.1016/S1470-2045(20)30336-3. Epub 2020 Jun 23.
8
Acute heart failure during lenvatinib plus pembrolizumab therapy.乐伐替尼联合帕博利珠单抗治疗期间的急性心力衰竭。
Int J Gynecol Cancer. 2022 Jun 6;32(6):817. doi: 10.1136/ijgc-2022-003532.
9
Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma.乐伐替尼联合帕博利珠单抗治疗肾细胞癌
N Engl J Med. 2021 Jul 15;385(3):287. doi: 10.1056/NEJMc2107518.
10
Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma.在一名接受过治疗的转移性胆管癌患者中，乐伐替尼与帕博利珠单抗联合治疗取得持久缓解。
J Gastrointestin Liver Dis. 2021 Sep 21;30(3):409-410. doi: 10.15403/jgld-3730.
引用本文的文献
1
A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma.一例使用帕博利珠单抗和乐伐替尼作为平滑肌肉瘤替代疗法的病例。
Gynecol Oncol Rep. 2023 Jan 27;45:101145. doi: 10.1016/j.gore.2023.101145. eCollection 2023 Feb.
本文引用的文献
1
Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.子宫和卵巢的混合性子宫内膜样腺癌和苗勒管腺肉瘤：强调与癌肉瘤鉴别诊断的临床病理特征。
Am J Surg Pathol. 2021 Mar 1;45(3):374-383. doi: 10.1097/PAS.0000000000001643.
2
Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.帕博利珠单抗联合仑伐替尼与帕博利珠单抗和仑伐替尼单药治疗癌症的安全性和有效性：系统评价。
Int Immunopharmacol. 2021 Feb;91:107281. doi: 10.1016/j.intimp.2020.107281. Epub 2020 Dec 16.
3
Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials.抗血管生成药物在肉瘤患者治疗中的应用：已发表试验综述
Front Oncol. 2020 Nov 24;10:594445. doi: 10.3389/fonc.2020.594445. eCollection 2020.
4
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.PD-L1 表达与子宫内膜癌中免疫组织化学确定的分子特征的相关性。
Virchows Arch. 2020 Dec;477(6):845-856. doi: 10.1007/s00428-020-02867-9. Epub 2020 Jun 27.
5
The immune microenvironment of uterine adenosarcomas.子宫腺肉瘤的免疫微环境
Clin Sarcoma Res. 2020 Mar 28;10:5. doi: 10.1186/s13569-020-0127-0. eCollection 2020.
6
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者。
J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13.
7
Systemic treatment in adult uterine sarcomas.成人子宫肉瘤的系统治疗。
Crit Rev Oncol Hematol. 2018 Feb;122:10-20. doi: 10.1016/j.critrevonc.2017.12.009. Epub 2017 Dec 14.
8
Treatment of Recurrent or Metastatic Uterine Adenosarcoma.复发性或转移性子宫腺肉瘤的治疗
Sarcoma. 2017;2017:4680273. doi: 10.1155/2017/4680273. Epub 2017 Dec 28.
9
Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.苗勒管腺肉瘤女性患者的生存情况：一项国家癌症数据库研究。
Gynecol Oncol. 2016 Dec;143(3):636-641. doi: 10.1016/j.ygyno.2016.10.013. Epub 2016 Oct 20.
10
Response of refractory Ewing sarcoma to pazopanib.难治性尤因肉瘤对帕唑帕尼的反应。
Acta Oncol. 2015 Jul;54(7):1063-4. doi: 10.3109/0284186X.2014.971938. Epub 2014 Oct 27.
Zotero 插件